日报更新时间：07-02 06:53
周报更新时间：01-16 11:49
今开价：18.21
最高价：18.5
成交量：1.14569E8
昨收价：17.99
最低价：17.77
最新价：18.06
中文名称：奥麦罗制药
英文名称：Omeros
行业：医疗
简介：Omeros Corporation是一家临床阶段的生物制药公司，致力于发现、开发和商业化针对炎症、中枢神经系统凝血紊乱的产品
电话：1-206-6765000
Omeros Corporation主要研发抑制发炎及中枢神经系统的药物和疗法。奥麦罗制药公司的商业化阶段的产品包括： Omidria——用于白内障手术的人工晶体置换。Omeros公司的临床阶段产品包括： OMS721——用于治疗各种补体介导的病症，包括补体介导的血栓微血管病，目前处于II期临床阶段； OMS824——用于治疗精神分裂症和亨廷顿氏病，目前处于II期临床试验阶段； OMS103——用于关节镜手术（如部分半月板切除术），已完成III期临床试验； OMS405——用于成瘾和药物滥用的治疗和预防，目前处于II期临床试验阶段； OMS201——用于泌尿外科疾病（如输尿管镜去除输尿管或肾结石），目前已经完成I / II临床试验。Omeros公司的临床前阶段产品包括： OMS527——用于治疗成瘾和强迫症，以及用于运动障碍，如帕金森氏病； OMS616——用于因手术、外伤或其他情况导致的失血； OMS906——用于阵发性睡眠性血红蛋白尿症和其他替代途径疾病的治疗； GPR17——用于脱髓鞘疾病的治疗； G蛋白偶联受体平台——可跨越治疗领域治疗多种疾病和障碍； 抗体平台——用于单克隆抗体的发现。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-06-06 | Kelbon (Marcia S) | General Counsel | Buy | 10000 | 6.05 |
| 2018-08-30 | Kelbon (Marcia S) | General Counsel | Buy | 7529 | 4.10 |
| 2018-08-30 | Kelbon (Marcia S) | General Counsel | Sell | 2192 | 25.31 |
| 2018-08-30 | Kelbon (Marcia S) | General Counsel | Buy | 8000 | 6.05 |
| 2018-08-30 | Kelbon (Marcia S) | General Counsel | Sell | 5337 | 25.93 |
| 2018-08-29 | Kelbon (Marcia S) | General Counsel | Buy | 35000 | 4.10 |
| 2018-08-29 | Kelbon (Marcia S) | General Counsel | Sell | 35000 | 24.45 |
| 2018-07-26 | Kelbon (Marcia S) | General Counsel | Sell | 5723 | 21.73 |
| 2018-07-26 | Kelbon (Marcia S) | General Counsel | Buy | 5723 | 4.10 |
| 2018-07-25 | Kelbon (Marcia S) | General Counsel | Sell | 35000 | 21.53 |
| 2018-07-25 | Kelbon (Marcia S) | General Counsel | Buy | 8000 | 6.05 |
| 2018-07-25 | Kelbon (Marcia S) | General Counsel | Buy | 35000 | 4.10 |
| 2018-07-11 | Kelbon (Marcia S) | General Counsel | Buy | 4277 | 4.10 |
| 2018-07-11 | Kelbon (Marcia S) | General Counsel | Sell | 4277 | 21.48 |
| 2018-05-14 | Jacobsen (Michael A) | Officer | Sell | 12812 | 24.95 |
| 2018-05-14 | Jacobsen (Michael A) | Officer | Buy | 12812 | 9.37 |
| 2018-05-14 | Jacobsen (Michael A) | Officer | Buy | 5000 | 9.37 |
| 2018-05-13 | Jacobsen (Michael A) | Officer | Buy | 10980 | 9.37 |
| 2018-05-13 | Jacobsen (Michael A) | Officer | Sell | 10980 | 22.45 |
| 2018-01-03 | Jacobsen (Michael A) | Officer | Buy | 1000 | 9.37 |
| 2018-01-02 | Jacobsen (Michael A) | Officer | Sell | 1020 | 22.45 |
| 2018-01-02 | Jacobsen (Michael A) | Officer | Buy | 1020 | 9.37 |
| 2018-01-02 | Kelbon (Marcia S) | General Counsel | Buy | 62528 | 9.37 |
| 2018-01-02 | Kelbon (Marcia S) | General Counsel | Buy | 5004 | 6.05 |
| 2018-01-02 | Kelbon (Marcia S) | General Counsel | Sell | 62528 | 21.45 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| American Financial Group Inc | 340284 | 0.69% | -- | -- | 2019-03-31 |
| State Street Corporation | 1056639 | 2.15% | -74011 | -6.55% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1318147 | 2.69% | -58 | -- | 2019-07-31 |
| Consonance Capital Management LP | 2124619 | 4.33% | 2124619 | -- | 2019-03-31 |
| BlackRock Fund Advisors | 2174211 | 4.43% | 10576 | 0.49% | 2019-07-31 |
| Vanguard Group Inc | 2372503 | 4.84% | 43769 | 1.88% | 2019-03-31 |
| D. E. Shaw & Co LP | 2585438 | 5.27% | 673194 | 35.20% | 2019-03-31 |
| BlackRock Inc | 3818051 | 7.78% | -171155 | -4.29% | 2019-03-31 |
| Ingalls & Snyder LLC | 5077257 | 10.35% | -93150 | -1.80% | 2019-03-31 |
| Northern Trust Investments Inc | 938258 | 1.91% | 16147 | 1.75% | 2019-07-31 |
| Millennium Management LLC | 748292 | 1.53% | -364292 | -32.74% | 2019-03-31 |
| CPCM, LLC | 721934 | 1.47% | -3614 | -0.50% | 2019-03-31 |
| UBS Group AG | 403411 | 0.82% | 1768 | 0.44% | 2019-03-31 |
| State Street Global Advisors | 444618 | 0.91% | -- | -- | 2019-07-31 |
| Fidelity Management & Research Company | 540619 | 1.10% | 23594 | 4.56% | 2019-07-31 |
| Geode Capital Management, LLC | 569289 | 1.16% | -463975 | -44.90% | 2019-03-31 |
| Northern Trust Investments N A | 630568 | 1.29% | 13395 | 2.17% | 2019-03-31 |
| Northern Trust Corp | 630568 | 1.29% | 13395 | 2.17% | 2019-03-31 |
| Stifel Nicolaus Investment Advisors | 634491 | 1.29% | 190813 | 43.01% | 2019-03-31 |
| Stifel Financial Corp | 634491 | 1.29% | 190813 | 43.01% | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 1091009 | 2.22% | 240 | 0.02% | 2019-05-31 |
| Royal Bank of Canada | 694793 | 1.42% | 693085 | 40578.75% | 2018-12-31 |
| Citadel Advisors Llc | 515279 | 1.05% | 515279 | -- | 2018-09-30 |
| Cormorant Asset Management, LLC | 1000000 | 2.04% | -314118 | -23.90% | 2018-09-30 |
| TIAA-CREF Investment Management LLC | 488748 | 1.00% | 248634 | 103.55% | 2018-09-30 |
| Susquehanna Financial Group, LLLP | 685876 | 1.40% | -269267 | -28.19% | 2018-09-30 |
| Susquehanna International Group, LLP | 685876 | 1.40% | -269267 | -28.19% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 1268387 | 2.59% | -2351 | -0.19% | 2018-06-30 |
| UBS Securities LLC | 382636 | 0.78% | -7810 | -2.00% | 2018-09-30 |
| Foresite Capital Management IV, LLC | 356000 | 0.73% | 356000 | -- | 2018-09-30 |
| Northern Trust Asset Management | 112184 | 0.23% | -326 | -0.29% | 2018-07-31 |
| BNY Mellon Investment Management | 133282 | 0.27% | 8079 | 6.45% | 2018-06-30 |
| Charles Schwab Investment Management Inc | 239828 | 0.49% | 17150 | 7.70% | 2018-06-30 |
| Morgan Stanley & Co Inc | 240148 | 0.50% | 92103 | 62.21% | 2018-06-30 |
| State Street Corp | 1079522 | 2.23% | -133006 | -10.97% | 2018-06-30 |
| Capital Impact Advisors, LLC | 95755 | 0.20% | -- | -- | 2018-06-30 |
| OZ Management LLC | 87400 | 0.18% | -- | -- | 2018-06-30 |
| Jefferies & Company Inc | 115708 | 0.24% | 115708 | -- | 2018-03-31 |
| Alps Advisors Inc | 76654 | 0.13% | -- | -- | 2018-08-10 |
| First Trust Advisors L.P. | 105884 | 0.22% | 105884 | -- | 2017-12-31 |
| Davenport & Company LLC | 79400 | 0.16% | -- | -- | 2017-12-31 |
| Candriam Luxembourg | 85370 | 0.18% | -8000 | -8.57% | 2017-12-31 |
| Mutual Of America Capital Management LLC | 109137 | 0.23% | 761 | 0.70% | 2017-12-31 |
| Group One Trading, LP | 150913 | 0.31% | 70899 | 88.61% | 2017-12-31 |
| Adage Capital Partners Gp LLC | 150000 | 0.31% | -- | -- | 2017-12-31 |
| Chicago Equity Partners LLC | 195120 | 0.40% | -755 | -0.39% | 2017-12-31 |
| Tocqueville Asset Management L.P. | 290119 | 0.60% | -190777 | -39.67% | 2017-12-31 |
| Great American Life Insurance Company | 429061 | 0.98% | -- | -- | 2016-12-31 |
| Invesco PowerShares Capital Mgmt LLC | 135876 | 0.28% | 135876 | -- | 2017-09-30 |
| EAM Investors | 202025 | 0.42% | 47146 | 30.44% | 2017-09-30 |
| EcoR1 Capital, LLC | 450000 | 0.94% | 450000 | -- | 2017-09-30 |
| Arrowstreet Capital Limited Partnership | 125643 | 0.26% | 125643 | -- | 2017-09-30 |
| Quantitative Investment Management, LLC | 149700 | 0.34% | 149700 | -- | 2017-06-30 |
| Think Investments LP | 524400 | 1.18% | 524400 | -- | 2017-06-30 |
| BMO Asset Management Corp. | 1972215 | 4.60% | 330598 | 20.14% | 2016-09-30 |
| Brown Investment Advisory Incorporated | 587508 | 1.37% | 43745 | 8.04% | 2016-09-30 |
| RTW INVESTMENTS, LLC | 383012 | 0.89% | -143776 | -27.29% | 2016-09-30 |
| Davidson D A & Co | 270245 | 0.63% | 7723 | 2.94% | 2016-09-30 |
| Manufacturers Life Insurance Co | 244976 | 0.57% | -1067 | -0.43% | 2016-09-30 |
| BlackRock Advisors LLC | 166765 | 0.39% | 7308 | 4.58% | 2016-09-30 |
| BlackRock, Inc. | 1953307 | 4.00% | 42875089 | -- | 1999-11-30 |
| Ingalls & Snyder, LLC | 2347987 | 4.00% | 51538315 | 0.10% | 1999-11-30 |
| Invesco, Ltd. | 3107443 | 4.00% | 68208374 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Schwab Small Cap Index Fund | 96875 | 0.20% | 2668 | 2.83% | 2019-06-30 |
| PNC Multi Factor Small Cap Core | 191075 | 0.39% | -20630 | -9.74% | 2019-05-31 |
| NT R2000 Growth Index Fund - Non-Lending | 195414 | 0.40% | -5714 | -2.84% | 2019-06-30 |
| State Street Russell Small/Mid Cap | 196930 | 0.40% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 427983 | 0.87% | 6060 | 1.44% | 2019-07-30 |
| iShares Nasdaq Biotechnology ETF | 484284 | 0.99% | 6651 | 1.39% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 643234 | 1.31% | -387 | -0.06% | 2019-06-30 |
| iShares Russell 2000 ETF | 1015602 | 2.07% | 1991 | 0.20% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 1308136 | 2.67% | -- | -- | 2019-06-30 |
| State Street Russell Small Cap | 190507 | 0.39% | -- | -- | 2019-06-30 |
| Fidelity | 186714 | 0.38% | 23599 | 14.47% | 2019-04-30 |
| SPDR | 104176 | 0.21% | -- | -- | 2019-07-30 |
| iShares Micro-Cap ETF | 117866 | 0.24% | -- | -- | 2019-07-30 |
| ERShares US Small Cap Fund | 119484 | 0.24% | -17086 | -12.51% | 2019-03-31 |
| Vanguard Health Care Index Fund | 120019 | 0.24% | -1281 | -1.06% | 2019-06-30 |
| Schwab US Small-Cap ETF | 133689 | 0.27% | -- | -- | 2019-07-30 |
| Northern Trust Russell 2000 Index DC NL | 135429 | 0.28% | 1191 | 0.89% | 2019-06-30 |
| NT R2000 Growth Index Fund - Lending | 140653 | 0.29% | 3883 | 2.84% | 2019-06-30 |
| NT R2000 Index Fund - NL | 178391 | 0.36% | 2171 | 1.23% | 2019-06-30 |
| Russell 2000 Index Non-Lendable Fund E | 94873 | 0.19% | 463 | 0.49% | 2019-03-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 941376 | 1.92% | -1584 | -0.17% | 2019-05-30 |
| CREF Stock Account | 206837 | 0.42% | -7042 | -3.29% | 2019-03-31 |
| iShares US Pharmaceuticals ETF | 106790 | 0.22% | -222 | -0.21% | 2019-03-29 |
| The Vanguard - Russell 2000 Grwth Idx CF | 82179 | 0.17% | 1050 | 1.29% | 2019-02-28 |
| AXA 2000 Managed Volatility Portfolio | 72435 | 0.15% | -- | -- | 2019-01-31 |
| Vanguard Russell 2000 Index Fund | 54465 | 0.11% | -828 | -1.50% | 2019-01-31 |
| Vanguard Instl Total Stock Market Idx Fd | 60160 | 0.12% | -- | -- | 2019-01-31 |
| Master Small Cap Index Series | 57883 | 0.12% | -- | -- | 2019-01-31 |
| TIAA-CREF Small-Cap Blend | 60948 | 0.12% | -- | -- | 2018-12-31 |
| Entrepreneur US Small Cap Fund | 95755 | 0.20% | -- | -- | 2018-09-30 |
| iShares Russell 2000 Small-Cap Index Fd | 57883 | 0.12% | 2676 | 4.85% | 2018-12-31 |
| Invesco DWA SmallCap Momentum ETF | 57281 | 0.12% | -- | -- | 2018-12-30 |
| ALPS Medical Breakthroughs ETF | 78470 | 0.16% | -- | -- | 2018-11-30 |
| Candriam Eqs L Biotechnology | 84000 | 0.17% | -- | -- | 2018-02-28 |
| Vanguard Market Neutral Fund | 155276 | 0.32% | 89700 | 136.79% | 2018-03-31 |
| Mutual of America Small Cap Growth Fund | 101107 | 0.21% | 1549 | 1.56% | 2017-12-31 |
| Invesco DWA Healthcare Momentum ETF | 101687 | 0.21% | -- | -- | 2017-09-30 |
| Vanguard Total Stock Mkt Idx | 1158369 | 2.39% | -- | -- | 2018-07-31 |
| iShares Nasdaq Biotechnology | 546702 | 1.12% | -1041 | -0.19% | 2018-09-12 |
| Vanguard Extended Market Idx Inv | 600526 | 1.24% | 801 | 0.13% | 2018-07-31 |
| iShares Russell 2000 Growth | 437092 | 0.90% | -421 | -0.10% | 2018-09-12 |
| iShares US Pharmaceuticals | 239177 | 0.49% | -- | -- | 2018-09-12 |
| CREF Stock R1 | 208055 | 0.43% | -2417 | -1.15% | 2018-07-31 |
| iShares Micro-Cap | 121691 | 0.25% | -- | -- | 2018-09-12 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 112184 | 0.23% | -326 | -0.29% | 2018-07-31 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 143388 | 0.32% | 3690 | 2.64% | 2017-06-30 |
| Vanguard Health Care ETF | 101960 | 0.21% | 3209 | 3.25% | 2018-07-31 |
| Fidelity Spartan | 96420 | 0.20% | -- | -- | 2018-07-31 |
| Schwab Small Cap Index | 86800 | 0.18% | -- | -- | 2018-07-31 |
| Entrepreneur US All Cap Institutional | 95755 | 0.20% | -- | -- | 2018-06-30 |
| The Vanguard Russell 2000 Growth Index | 82141 | 0.17% | 1044 | 1.29% | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 70786 | 0.15% | -- | -- | 2018-07-31 |
| AXA 2000 Managed Volatility K | 68089 | 0.14% | -- | -- | 2018-07-31 |
| BlackRock Extended Equity Market K | 77655 | 0.16% | 16985 | 28.00% | 2018-06-30 |
| Vanguard Market Neutral I | 155276 | 0.32% | 89700 | 136.79% | 2018-03-31 |
| BlackRock Russell 2000 | 67541 | 0.14% | -2443 | -3.49% | 2018-06-30 |
| BioShares | 41704 | 0.09% | -- | -- | 2018-06-01 |
| Mutual of America Small Cap Growth | 101107 | 0.21% | 1549 | 1.56% | 2017-12-31 |
| Vanguard Strategic Small-Cap Equity Inv | 43475 | 0.09% | 43475 | -- | 2017-12-31 |
| JNL/Mellon Capital Healthcare Sector B | 41519 | 0.09% | 10410 | 33.46% | 2017-12-31 |
| BlackRock Russell 2500 | 61830 | 0.13% | 316 | 0.51% | 2017-12-31 |
| iShares Russell 2000 Value | 138647 | 0.34% | -552 | -0.40% | 2017-02-07 |
| Tocqueville Alternative Strategies | 75000 | 0.19% | 10000 | 15.38% | 2016-03-31 |
| JNL Multi-Manager Small Cap Value A | 81475 | 0.19% | 7165 | 9.64% | 2016-09-30 |
| SSgA Russell Small/Mid Cap Index Fund Tr | 87400 | 0.20% | -- | -- | 2015-06-30 |
| Mackenzie US Growth Class | 92000 | 0.20% | -- | -- | 2015-08-31 |
| Principal SmallCap Growth Fund I | 115165 | 0.30% | 1431 | 1.30% | 2015-10-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 129021 | 0.30% | -- | -- | 2015-09-30 |
| Tocqueville Fund | 150000 | 0.40% | -- | -- | 2015-09-30 |
| BMO Small Cap Growth Fund | 383994 | 1.00% | 383994 | -- | 2015-09-30 |
| iShares Russell 2000 (AU) | 603295 | 1.70% | -762 | -0.10% | 2015-11-19 |
| SPDR® S&P Pharmaceuticals ETF | 1483826 | 4.30% | -- | -- | 2015-11-19 |
| Arnold C. Hanish | Arnold C. Hanish is on the board of Omeros Corp. and Member-Audit Quality Review Council at Deloitte & Touche LLP. He previously was Chief Accounting Officer & Vice President of Eli Lilly & Co. He received an undergraduate degree from the University of Cincinnati (Ohio). |
|---|---|
| Timothy M. Duffy | Founder of Pacific Crest Corp. and Pacific Crest Ventures, Timothy M. Duffy is Vice President-Business Development of Omeros Corp. In the past Mr. Duffy occupied the position of Managing Director at Pacific Crest Ventures, Manager-Customer Marketing at Procter & Gamble Co., Managing Director at Pacific Crest Corp., Vice President-Business Development of Prometheus Laboratories, Inc. and Chief Business Officer for MDRNA, Inc. Timothy M. Duffy received an undergraduate degree from Loras College. |
| Leroy E. Hood | Dr. Leroy E. Hood, is President at The Institute for Systems Biology, President at ISB Accelerator Corp., an Advisor at InterWest Partners, Co-Founder at Rosetta Inpharmatics LLC, Founder at University of Washington, Co-Founder at Systemix, Inc., Co-Founder at Darwin Molecular Technologies, Inc., a Member at National Academy of Sciences, a Member at American Philosophical Society, a Member at The American Association of Arts & Sciences, a Member at National Academy of Engineering, a Member at Institute of Medicine, a Director at Accelerator Corp., an Advisor at OVP Venture Partners, a Director at Integrated Diagnostics, Inc. (Washington), and a Director at Science Foundation Arizona. He is on the Board of Directors at NABsys, Inc., Omeros Corp., Intelligent Medical Devices, Inc., Integrated Diagnostics, Inc. (Washington), and Geospiza, Inc. Dr. Hood was previously employed as Co-Founder by Applied Biosystems, Inc., a Principal by Rosetta Genomics Ltd., a Principal by Amgen, Inc., a Principal by Applied Biosystems, Inc., and a Principal by Darwin Resources, Inc. He also served on the board at Icoria, Inc., CTI Molecular Imaging, Inc., Lynx Therapeutics, Inc., and NimbleGen Systems, Inc. Dr. Hood received his undergraduate degree from the California Institute of Technology, a doctorate degree from Johns Hopkins University, and a doctorate degree from the California Institute of Technology. |
| Michael A. Jacobsen | Michael A. Jacobsen is Principal Financial Officer, Treasurer & VP at Omeros Corp. In his past career he occupied the position of Secretary, Chief Accounting Officer & VP-Finance at Sarepta Therapeutics, Inc., Chief Accounting Officer & Vice President for ZymoGenetics, Inc. and Senior Director-Finance & Corporate Controller at ICOS Corp. He received an undergraduate degree from Idaho State University. |
| Rajiv J. Shah | Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine. |
| Thomas J. Cable | Thomas J. Cable is an entrepreneur who founded Cable & Howse Ventures, Cable, Howse & Ragen, Inc. and Washington Research Foundation. Mr. Cable is on the board of Omeros Corp., Institute for Systems Biology and Washington Research Foundation. In his past career Thomas J. Cable was Partner at Cable, Howse & Ragen, Inc. and Chairman for WRF Capital. Mr. Cable received an undergraduate degree from Harvard University and an MBA from Stanford Graduate School of Business. |
| George A. Gaitanaris | George A. Gaitanaris founded Primal, Inc. and Nura, Inc. Presently, Dr. Gaitanaris occupies the position of Chief Scientific Officer & Vice President-Science at Omeros Corp. In his past career he held the position of President & Chief Scientific Officer at Primal, Inc., Chief Scientific Officer at Nura, Inc. and Staff Scientist at National Cancer Institute. George A. Gaitanaris received a graduate degree and a doctorate from Columbia University and a doctorate from Aristotle University of Thessaloniki. |
| Gregory A. Demopulos | Gregory A. Demopulos founded Omeros Corp. Presently, he is Chairman, President & Chief Executive Officer at this company. He is also on the board of Onconome, Inc., Smead Funds Trust, Tessera, Inc. and Northwest NeuroNeighborhood and Member of Seattle Cardiology. He received an undergraduate degree from Stanford University and a doctorate from Stanford University School of Medicine. |
| Marcia S. Kelbon | Presently, Marcia S. Kelbon holds the position of Vice President-Legal Affairs at Omeros Corp. She is also Member of Washington State Bar Association. Ms. Kelbon previously was Partner at Christensen O'Connor Johnson & Kindness PLLC. She received a graduate degree from the University of Washington and an undergraduate degree from The Pennsylvania State University. |
| Ray Aspiri | Ray Aspiri founded Tempress Technologies, Inc. He is on the board of Omeros Corp. Mr. Aspiri previously was Chairman & Chief Executive Officer at Tempress, Inc., Chairman & Chief Executive Officer for Tempress Associates, Inc. and Chairman at Tempress Technologies, Inc. |
| Peter A. Demopulos | Peter A. Demopulos occupies the position of Member of Seattle Cardiology. He is also on the board of Omeros Corp. and Assistant Professor at UW Medicine. He received an undergraduate degree from Stanford University and a doctorate from Stanford University School of Medicine. |
| Rajiv J. Shah | Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine. |
| J. Steven Whitaker | J. Steven Whitaker is Head-Clinical Aspects at Omeros Corp. In the past Dr. Whitaker held the position of Chief Medical Officer & VP-Clinical Development at Allon Therapeutics, Inc. and Divisional Vice President at ICOS Corp. Dr. Whitaker received a graduate degree from the University of Washington, an undergraduate degree from Butler University and a doctorate from The Indiana University School of Medicine. |
| Thomas F. Bumol | Thomas F. Bumol is on the board of Omeros Corp., PanTheryx, Inc. and Allen Institute For Immunology. Dr. Bumol previously held the position of Senior VP-Biotechnology & Autoimmunity Research at Eli Lilly & Co. President of Applied Molecular Evolution, Inc. and President-Applied Molecular Evolution at Lilly Research Laboratories (both are subsidiaries of Eli Lilly & Co.). Thomas F. Bumol received an undergraduate degree from the University of Michigan and a doctorate from the University of Minnesota. |
| Peter B. Cancelmo | Presently, Peter B. Cancelmo is Secretary, Vice President & General Counsel at Omeros Corp. Mr. Cancelmo previously was Principal at Garvey Schubert Barer. Mr. Cancelmo received a graduate degree from Boston University and an undergraduate degree from St. Michael's College. |
| Timothy M. Duffy | Founder of Pacific Crest Corp. and Pacific Crest Ventures, Timothy M. Duffy is Vice President-Business Development of Omeros Corp. In the past Mr. Duffy occupied the position of Managing Director at Pacific Crest Ventures, Manager-Customer Marketing at Procter & Gamble Co., Managing Director at Pacific Crest Corp., Vice President-Business Development of Prometheus Laboratories, Inc. and Chief Business Officer for MDRNA, Inc. Timothy M. Duffy received an undergraduate degree from Loras College. |
| Catherine A. Melfi | Currently, Catherine A. Melfi is Chief Regulatory Officer & VP-Regulatory Affairs at Omeros Corp. Dr. Melfi previously held the position of Scientific Director-Regulatory Affairs at Eli Lilly & Co. She received a doctorate from the University of North Carolina at Chapel Hill and an undergraduate degree from John Carroll University. |
| Rajiv J. Shah | Rajiv J. Shah is on the board of Omeros Corp., PanTheryx, Inc., International Rescue Committee, Inc. and The Nature Conservancy, Inc. and President & Trustee at The Rockefeller Foundation. He previously was Managing Partner at Latitude Capital Partners LLC, Chief Scientist & Undersecretary at USDA Rural Development and Administrator at US Agency for International Development. Rajiv J. Shah received a graduate degree from The Wharton School of the University of Pennsylvania, an undergraduate degree from the University of Michigan and a doctorate from Perelman School of Medicine. |
| Michael A. Jacobsen | Michael A. Jacobsen is Principal Financial Officer, Treasurer & VP at Omeros Corp. In his past career he occupied the position of Secretary, Chief Accounting Officer & VP-Finance at Sarepta Therapeutics, Inc., Chief Accounting Officer & Vice President for ZymoGenetics, Inc. and Senior Director-Finance & Corporate Controller at ICOS Corp. He received an undergraduate degree from Idaho State University. |
| Timi Edeki | Timi Edeki is Vice President-Clinical Development at Omeros Corp. In the past he held the position of Senior Director-Research & Development at AstraZeneca Diagnostics, Associate Director at Abbott Laboratories and Professor at Chicago Medical School. He received a doctorate from the University of London and an undergraduate degree from the University of Lagos. |
| Eckhard S. D. Leifke | Currently, Eckhard S. D. Leifke holds the position of Chief Medical Officer & VP-Clinical Development at Omeros Corp. In the past he was Vice President for Sanofi, Inc. Dr. Leifke received a doctorate from the University of Freiburg. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论